Phase 1 N=40 Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Plasma Concentrations
Primary: Cmax — 34.96; 249.55 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,862 A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
Myocardial Infarction · Segment Elevation Myocardial Infarction (STEMI)
Primary: Thrombolysis In Myocardial Infarction (TIMI) Flow Grade 3 of MI Culprit Vessel at Initial Angiography (Co-primary Endpoint) — 143; 145 patients — p=0.8214
N/A N=50 A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray
Skin Care
Primary: Participant-perceived Cooling Sensation Immediately Post Product Application — 30.63; 30.15; 25.16 Score on a scale — p=0.0659
N/A N=150 A Prospective Trial of Ultrasound Versus Landmark Guided Central Venous Access in the Pediatric Population
Need for Central Venous Access
Primary: Success of Central Venous Cannulation at First Attempt — 38; 43 Participants
Phase 1 N=30 Safety and Immunogenicity Study of Recombinant Ricin Toxin A-Chain Vaccine (RVEc™)
Ricin
Primary: Number of Vaccinated Subjects Any Averse Events and by Location and Severity — 10; 10; 9; 0 participants
Phase 4 N=120 Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Total (Cumulative) Dose Delivery of Sorafenib — 49800; 38000 mg — p=0.0262
Phase 1 N=40 A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
Smoking
Primary: Area Under the Curve From Time 0 to the Last Quantifiable Sample, AUC(0-t) — 494.54; 528.43 nanogram (ng)*hour (hr)/milliliter (mL)
N/A N=27 Effects of Pediatric Aquatic Therapy in Children With Spastic Cerebral Palsy
Spastic Cerebral Palsy
Primary: Unit on Gross Motor Function Measure Scale (GMFM) — 5.12; 2.00 units on a scale — p=0.007
Phase 3 N=149 An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)
Fibromyalgia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 138 participants
Phase 2 N=49 A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Primary: Number of Patients That Achieved a Complete Response or a Partial Response (PR) — 32 participants
Phase 2 N=100 Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Chronic Plaque Psoriasis
Primary: Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores — -12.46; -13.35; -18.02; -4.18 scores on a scale
N/A N=27 Clinical Feasibility of New Tracheoesophageal Puncture Set
Larynx Cancer
Primary: Success Rate of Procedure — 23 Nr part. with succesful insertions
Phase 3 N=300 BOTOX® in the Treatment of Crow's Feet Lines in Japan
Lateral Canthus Rhytides · Crow's Feet Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 4 N=10 12-Month Stability of Diurnal IOP Control on Cosopt
Glaucoma
Primary: Diurnal Intraocular Pressure Control — -4.4 millimeters of mercury
Phase 3 N=101 BOTOX® in the Treatment of Upper Facial Lines in Japan
Upper Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…